Balaji Prasad
Stock Analyst at Barclays
(2.78)
# 1,814
Out of 5,150 analysts
147
Total ratings
49.19%
Success rate
4.67%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $5.59 | +347.23% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $13.30 | -17.29% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $22.86 | +4.99% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $14.71 | -38.82% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $188.69 | +5.99% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $24.44 | -22.26% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $76.20 | -21.26% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $125.96 | +93.71% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $6.87 | +249.34% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $51.89 | -57.60% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $648.70 | -19.84% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $32.91 | -21.00% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $208.95 | -23.43% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.28 | +19.05% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $3.89 | +362.72% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.25 | +135.29% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.76 | +297.73% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $5.59
Upside: +347.23%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $13.30
Upside: -17.29%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $22.86
Upside: +4.99%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $14.71
Upside: -38.82%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $188.69
Upside: +5.99%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $24.44
Upside: -22.26%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $76.20
Upside: -21.26%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $125.96
Upside: +93.71%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $6.87
Upside: +249.34%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $51.89
Upside: -57.60%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $648.70
Upside: -19.84%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $32.91
Upside: -21.00%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $208.95
Upside: -23.43%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.28
Upside: +19.05%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $3.89
Upside: +362.72%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.25
Upside: +135.29%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.76
Upside: +297.73%